Literature DB >> 27084958

Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy.

Fleur M van der Valk1, Sophie J Bernelot Moens1, Simone L Verweij1, Aart C Strang1, Aart J Nederveen2, Hein J Verberne3, Michael T Nurmohamed4, Dominique L Baeten5, Erik S G Stroes1.   

Abstract

BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory disease with involvement of axial and sacroiliac joints. In addition, patients with AS have increased risk of cardiovascular disease (CVD), which might be attributed to enhanced inflammatory activity of the arterial wall. In the present study, we compared the level of carotid arterial wall inflammation in patients with AS with healthy controls using (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography with CT. As arterial wall inflammation is reduced by statin therapy, we subsequently assessed the effect of 3-month statin therapy on arterial wall inflammation in AS. METHODS AND
RESULTS: We included 24 patients with AS (age 44±10, 72% males) without a history of CVD and 20 controls matched for age and gender. Patients with AS had lower high-density lipoprotein cholesterol and increased C reactive protein (CRP) compared with controls. The 10-year CVD risk was 2% in both groups. Notwithstanding, patients with AS had a 20% increase in arterial wall (18)F-FDG uptake compared with controls. Three-month atorvastatin 40 mg daily significantly lowered low-density lipoprotein cholesterol (baseline 3.55±1.15 mmol/L, -53%) and CRP (baseline 5.0 (1.5-9.3) mg/L, -58%) with a concomitant decrease of carotid arterial wall inflammation (maximum target-to-background ratio from 1.90±0.30 to 1.67±0.27; p=0.009).
CONCLUSIONS: Patients with AS and without other CVD risk factors have increased arterial wall inflammation, which decreases upon statin therapy. These subjects are not identified as being at risk in current cardiovascular prevention guidelines. Our data support the need to revise CV disease management in AS, with perhaps a role for early statin therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Ankylosing Spondylitis; Atherosclerosis; Cardiovascular Disease; Inflammation; Treatment

Mesh:

Substances:

Year:  2016        PMID: 27084958     DOI: 10.1136/annrheumdis-2016-209176

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.

Authors:  Lotte C A Stiekema; Erik S G Stroes; Simone L Verweij; Helina Kassahun; Lisa Chen; Scott M Wasserman; Marc S Sabatine; Venkatesh Mani; Zahi A Fayad
Journal:  Eur Heart J       Date:  2019-09-01       Impact factor: 29.983

2.  Spondyloarthropathies: CVD prevention and statin therapy in ankylosing spondylitis.

Authors:  Anne Grete Semb; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2016-06-30       Impact factor: 20.543

3.  Arterial Inflammation Detected With 18 F-Fluorodeoxyglucose-Positron Emission Tomography in Rheumatoid Arthritis.

Authors:  Laura Geraldino-Pardilla; Afshin Zartoshti; Ayse Bag Ozbek; Jon T Giles; Richard Weinberg; Mona Kinkhabwala; Sabahat Bokhari; Joan M Bathon
Journal:  Arthritis Rheumatol       Date:  2017-12-01       Impact factor: 10.995

4.  Cardiovascular events prediction by left ventricular longitudinal strain and serum high-sensitivity troponin I in patients with axial spondyloarthritis.

Authors:  Yan Chen; Yap-Hang Chan; Ho-Yin Chung; Mei-Zhen Wu; Yu-Juan Yu; Kang-Li Pi; Chak-Sing Lau; Hung-Fat Tse; Kai-Hang Yiu
Journal:  Clin Rheumatol       Date:  2020-05-13       Impact factor: 2.980

Review 5.  Comorbidities in Spondyloarthritis.

Authors:  Anna Moltó; Elena Nikiphorou
Journal:  Front Med (Lausanne)       Date:  2018-03-12

6.  Relationships Between the Cardio-Ankle Vascular Index and Pulsatility Index of the Common Carotid Artery in Patients With Cardiovascular Risk Factors.

Authors:  Takashi Hitsumoto
Journal:  J Clin Med Res       Date:  2019-07-27

7.  Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease.

Authors:  Renate M Hoogeveen; Simone L Verweij; Yannick Kaiser; Jeffrey Kroon; Hein J Verberne; Liffert Vogt; Sophie J Bernelot Moens; Erik S G Stroes
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

Review 8.  Advances in HDL: Much More than Lipid Transporters.

Authors:  Soumaya Ben-Aicha; Lina Badimon; Gemma Vilahur
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

9.  The rs6427384 and rs6692977 Single Nucleotide Polymorphisms of the Fc Receptor-Like 5 (FCRL5) Gene and the Risk of Ankylosing Spondylitis: A Case Control Study in a Single Center in China.

Authors:  Hua-Wei Liu; Dai-Xu Wei; Da-Wei He; Jiu-Zheng Deng; Jian-Jin Zhu; Kai Xu; Dong Hu; Jing Li; Wen-Hao Hu; Yan Wang; Song-Hua Xiao; Li-Gong Fu
Journal:  Med Sci Monit       Date:  2020-09-06

Review 10.  Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation.

Authors:  Andrej Ćorović; Christopher Wall; Justin C Mason; James H F Rudd; Jason M Tarkin
Journal:  Curr Cardiol Rep       Date:  2020-08-09       Impact factor: 3.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.